Evidence map›Paper›PMID 31375570›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

The Genetic Duet of

Jiajun Liu, Rengyun Liu, Xiaopei Shen, Guangwu Zhu, Biao Li, Mingzhao Xing

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 6 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 6 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The effect ofFrontiers in endocrinology · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jiajun LiuLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Rengyun LiuLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Xiaopei ShenLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Guangwu ZhuLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Biao LiDepartment of Nuclear Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mingzhao XingLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and mxing1@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USShanghai Jiao Tong University · CN

Funding

TERT Promoter Mutations in Thyroid CancerR01CA189224 · NCI · JOHNS HOPKINS UNIVERSITY · PI XING, MICHAEL MINGZHAO · 2015 to 2019
$1.8M
Molecular Events in the PI3K/AKT Pathway in Thyroid CancerR01CA215142 · NCI · JOHNS HOPKINS UNIVERSITY · PI XING, MICHAEL MINGZHAO · 2018 to 2019
$723k
NCI NIH HHS R01 CA189224NCI NIH HHS R01 CA215142
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAdultAgedCohort StudiesFemaleGenotypeHumansIodine RadioisotopesMaleMiddle AgedPrognosisPromoter Regions, GeneticProto-Oncogene Proteins B-rafRecurrenceTelomeraseThyroid Cancer, PapillaryBRAF protein, humanIodine RadioisotopesProto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAF V600Eradioiodine therapyrecurrenceTERT promoter mutationthyroid cancer

Identifiers

PMID31375570
PMCPMC8801951
OpenAlexW2964573638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.